Cooper G J
Amylin Corporation, San Diego, CA 92121.
Med Hypotheses. 1991 Nov;36(3):284-8. doi: 10.1016/0306-9877(91)90150-w.
Amylin is a proteinaceous hormone secreted form insulin-producing pancreatic beta-cells following stimulation by food molecules such as glucose and arginine. Amylin decreases insulin-stimulated glucose uptake in skeletal muscle and counteracts the ability of insulin to suppress output of glucose from the liver. Substantial evidence supports the view that maylin is a second glucoregulatory hormone produced from islet beta-cells, which can modulate a number of metabolic processes also regulated by insulin. The islet beta-cell may therefore transmit a dual message to peripheral tissues through the two hormones, insulin and amylin. Like insulin, amylin is deficient in individuals with autoimmune diabetes mellitus. Since amylin can modulate processes of fuel metabolism in key tissues, amylin deficiency could contribute to the clinical course in patients with autoimmune diabetes. Here, I propose that amylin lack plays a significant role to promote the tendency to hypoglycemia and defective glycemic control characteristic of insulin-treated patients with autoimmune diabetes. Treatment of such diabetics with injections of amylin as well as insulin is being evaluated with the aim of lessening the incidence and severity of hypoglycemia and improving glycemic control.
胰淀素是一种蛋白质类激素，由产生胰岛素的胰腺β细胞在受到葡萄糖和精氨酸等食物分子刺激后分泌。胰淀素可降低胰岛素刺激的骨骼肌对葡萄糖的摄取，并抵消胰岛素抑制肝脏葡萄糖输出的能力。大量证据支持这样一种观点，即胰淀素是胰岛β细胞产生的第二种葡萄糖调节激素，它可以调节许多也受胰岛素调节的代谢过程。因此，胰岛β细胞可能通过胰岛素和胰淀素这两种激素向周围组织传递双重信息。与胰岛素一样，自身免疫性糖尿病患者体内缺乏胰淀素。由于胰淀素可以调节关键组织中的燃料代谢过程，胰淀素缺乏可能会影响自身免疫性糖尿病患者的临床病程。在此，我提出胰淀素缺乏在促进胰岛素治疗的自身免疫性糖尿病患者低血糖倾向和血糖控制缺陷方面起重要作用。目前正在评估给这类糖尿病患者注射胰淀素以及胰岛素的治疗方法，目的是降低低血糖的发生率和严重程度，并改善血糖控制。
